HK1069785A1 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases - Google Patents

Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Info

Publication number
HK1069785A1
HK1069785A1 HK05102326.6A HK05102326A HK1069785A1 HK 1069785 A1 HK1069785 A1 HK 1069785A1 HK 05102326 A HK05102326 A HK 05102326A HK 1069785 A1 HK1069785 A1 HK 1069785A1
Authority
HK
Hong Kong
Prior art keywords
treatment
diseases
superoxide dismutase
ocular disorders
dismutase mimics
Prior art date
Application number
HK05102326.6A
Other languages
English (en)
Inventor
Robert J Collier Jr
Mark R Hellberg
Peter G Klimko
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of HK1069785A1 publication Critical patent/HK1069785A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK05102326.6A 2001-12-14 2005-03-17 Superoxide dismutase mimics for the treatment of ocular disorders and diseases HK1069785A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34038901P 2001-12-14 2001-12-14
PCT/US2002/039037 WO2003051458A1 (en) 2001-12-14 2002-12-06 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Publications (1)

Publication Number Publication Date
HK1069785A1 true HK1069785A1 (en) 2005-06-03

Family

ID=23333158

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102326.6A HK1069785A1 (en) 2001-12-14 2005-03-17 Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Country Status (19)

Country Link
US (2) US7759333B2 (xx)
EP (1) EP1463563B1 (xx)
JP (1) JP2005513063A (xx)
KR (1) KR100951606B1 (xx)
CN (2) CN101092432A (xx)
AT (1) ATE422944T1 (xx)
BR (1) BR0214957A (xx)
CA (1) CA2470721C (xx)
CY (1) CY1108983T1 (xx)
DE (1) DE60231246D1 (xx)
DK (1) DK1463563T3 (xx)
ES (1) ES2319399T3 (xx)
HK (1) HK1069785A1 (xx)
MX (1) MXPA04005601A (xx)
PL (1) PL210225B1 (xx)
PT (1) PT1463563E (xx)
SI (1) SI1463563T1 (xx)
WO (1) WO2003051458A1 (xx)
ZA (1) ZA200404435B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101092432A (zh) * 2001-12-14 2007-12-26 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
JP5683484B2 (ja) 2008-12-19 2015-03-11 ジェネンテック， インコーポレイテッド 化合物と使用法
PL2433640T3 (pl) 2010-09-24 2020-06-01 Omnivision Gmbh Kompozycja zawierająca SOD, luteinę i zeaksantynę
KR101214364B1 (ko) * 2011-02-15 2012-12-21 한림대학교 산학협력단 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
US9149483B2 (en) * 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
WO2023120828A1 (ko) * 2021-12-23 2023-06-29 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
WO2023224136A1 (ko) * 2022-05-16 2023-11-23 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
SE9402816D0 (sv) 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
CA2309154C (en) * 1997-11-03 2010-02-16 Duke University Substituted porphyrins
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
DE60018925T2 (de) 1999-05-27 2006-04-13 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
CN101092432A (zh) 2001-12-14 2007-12-26 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物

Also Published As

Publication number Publication date
PT1463563E (pt) 2009-03-19
CA2470721C (en) 2011-07-12
ZA200404435B (en) 2006-05-31
WO2003051458A1 (en) 2003-06-26
BR0214957A (pt) 2004-12-14
DK1463563T3 (da) 2009-04-20
SI1463563T1 (sl) 2009-06-30
CA2470721A1 (en) 2003-06-26
DE60231246D1 (de) 2009-04-02
MXPA04005601A (es) 2004-12-06
ES2319399T3 (es) 2009-05-07
US8003635B2 (en) 2011-08-23
PL369607A1 (en) 2005-05-02
ATE422944T1 (de) 2009-03-15
CY1108983T1 (el) 2014-07-02
EP1463563A1 (en) 2004-10-06
CN101092432A (zh) 2007-12-26
EP1463563B1 (en) 2009-02-18
AU2002351267A1 (en) 2003-06-30
KR20040063943A (ko) 2004-07-14
KR100951606B1 (ko) 2010-04-09
CN1620325A (zh) 2005-05-25
JP2005513063A (ja) 2005-05-12
US7759333B2 (en) 2010-07-20
AU2002351267B2 (en) 2007-04-05
US20050032768A1 (en) 2005-02-10
US20100204194A1 (en) 2010-08-12
PL210225B1 (pl) 2011-12-30

Similar Documents

Publication Publication Date Title
HK1069785A1 (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
WO2004052227A3 (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
WO2002085248A3 (en) Prostanoids augment ocular drug penetration
WO2006069078A3 (en) Treatment of anal incontinence
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
AU780906C (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
AP1750A (en) Methods for treating ocular neovascular diseases
PL396553A1 (pl) Zastosowanie czynnika do wytwarzania leku do leczenia jaskry
WO2006100677A3 (en) Device and method for pupil size modulation
AU2002234806A1 (en) Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
MXPA03010655A (es) Gel oft??lmico de pirenzepina.
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
MXPA04000124A (es) Composicion farmaceutica para la terapia de cistitis intersticial.
MXPA03009273A (es) AGENTE PARA EL TRATAMIENTO OFTaLMICO TOPICO DE LAS ENFERMEDADES INFLAMATORIAS OCULARES.
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
BR0017163A (pt) Derivados 5-hidróxi-indazol para tratamento do glaucoma
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
EP1567166A4 (en) SUPEROXIDE DISMUTASE MIMIC FOR THE TREATMENT OF EYE DISORDER AND DISEASES
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
PT1178819E (pt) Glutationa-redutase para a terapia e profilaxia da sida
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171206